DNA Copy Number Signature to Predict Recurrence in Early-Stage Ovarian Cancer
Technical Report,01 Aug 2014,31 Jul 2017
Massachusetts General Hospital Boston United States
Pagination or Media Count:
Through this project we have determined the status of copy number variation in recurrent and non-recurrent early stage high grade ovarian cancer using a large, fully annotated, consortium cohort of 384 samples from clinical trials Aim 1. Integrated analysis of copy number variation and RNAseq results from same samples generated from an ongoing DOD OC110628 has been performed with clinical data to generate a predictor of the recurrence of early stage ovarian cancer Aim 2.
- Medicine and Medical Research